How quickly can hyperkalemic cardiac arrest occur in a child with muscular dystrophy after receiving succinylcholine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hyperkalemic Cardiac Arrest Timing in Muscular Dystrophy After Succinylcholine

Cardiac arrest can occur within minutes of succinylcholine administration in children with muscular dystrophy, presenting as sudden asystole or ventricular dysrhythmias immediately following injection. 1, 2, 3

Immediate Onset and Clinical Timeline

The syndrome typically presents as sudden cardiac arrest within minutes after succinylcholine administration, with the FDA labeling explicitly warning that "the syndrome often presents as sudden cardiac arrest within minutes after the administration of succinylcholine" in pediatric patients with undiagnosed skeletal muscle myopathies such as Duchenne muscular dystrophy. 3

  • Cardiac arrest occurs so rapidly that routine resuscitative measures are likely to be unsuccessful unless hyperkalemia is immediately suspected and treated aggressively. 3

  • The American College of Chest Physicians documents numerous reports of sudden death due to hyperkalemic cardiac arrest associated with succinylcholine in patients with Duchenne muscular dystrophy, emphasizing the immediate nature of this catastrophic event. 1

  • Case reports consistently demonstrate arrest occurring within the first few minutes following succinylcholine injection, with one documented case showing cardiac arrest in a 3-year-old boy immediately after a single dose during halothane anesthesia. 4

Pathophysiology Explaining Rapid Onset

Succinylcholine disrupts unstable dystrophic muscle cell membranes, causing acute rhabdomyolysis with massive potassium efflux into the circulation. 1, 2

  • When upregulated nicotinic acetylcholine receptors (which migrate across the entire muscle membrane surface in muscular dystrophy) are depolarized by succinylcholine, massive potassium release occurs instantaneously. 2

  • The American College of Chest Physicians states that succinylcholine, as a depolarizing muscle relaxant, disrupts unstable cell membranes and has been linked to acute rhabdomyolysis, hyperkalemia, and cardiac arrest in DMD patients. 1

  • Documented cases show serum potassium levels reaching 12.57 mEq/L during arrest, with mean potassium levels of 7.4 ± 2.8 mmol/L in pediatric arrests associated with succinylcholine. 5, 6

Critical Warning Signs

Peaked T-waves on ECG represent the earliest detectable sign of hyperkalemia, though cardiac arrest may occur before this can be recognized. 3

  • The FDA warns that "careful monitoring of the electrocardiogram may alert the practitioner to peaked T-waves (an early sign)" but acknowledges that due to the abrupt onset, routine resuscitative measures are likely unsuccessful. 3

  • Lack of fasciculations after succinylcholine administration may be an ominous sign in these patients, as documented in case reports of arrest in undiagnosed DMD. 4

  • The American Academy of Pediatrics warns that cardiac arrest occurring immediately after succinylcholine should prompt immediate suspicion of hyperkalemia, particularly in young male patients. 2

Absolute Contraindication

Succinylcholine is absolutely contraindicated in all patients with known or suspected muscular dystrophy. 1, 2, 3

  • The American College of Chest Physicians states that "succinylcholine is widely recognized to be contraindicated in patients with DMD" based on numerous reports of sudden death. 1

  • The FDA recommends that "the use of succinylcholine in pediatric patients should be reserved for emergency intubation or instances where immediate securing of the airway is necessary" specifically because of this risk. 3

  • Most affected patients are males, most frequently 8 years of age or younger, though adolescents have also been affected. 3

Emergency Management Protocol

If cardiac arrest occurs immediately after succinylcholine, treat hyperkalemia aggressively with intravenous calcium, insulin/glucose, sodium bicarbonate, and hyperventilation. 3, 5

  • The FDA states that "administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation have resulted in successful resuscitation in some of the reported cases." 3

  • Extraordinary and prolonged resuscitative efforts have been effective in some cases, with documented successful resuscitations after 10-42 minutes of CPR when hyperkalemia was treated. 3, 7, 6

  • Case reports document successful restoration of cardiac activity without neurological sequelae when aggressive treatment for hyperkalemia was initiated during prolonged resuscitation efforts. 7

High-Risk Population Identification

Male children undergoing elective procedures are at highest risk, particularly those with subtle developmental delays or elevated creatine kinase levels. 3, 6

  • The FDA notes that "there may be no signs or symptoms to alert the practitioner to which patients are at risk" and that "a careful history and physical may identify developmental delays suggestive of a myopathy." 3

  • A preoperative creatine kinase measurement could identify some but not all patients at risk, with one study suggesting that 64% of arrests and 60% of deaths might have been prevented with CK screening in male patients. 3, 6

  • In one case series, 92% of patients who arrested were male with a median age of 45 months, and 92% were scheduled for minor elective surgery. 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Succinylcholine Safety After Receptor Upregulation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Duchenne muscular dystrophy and malignant hyperthermia--two case reports.

Canadian Anaesthetists' Society journal, 1986

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.